Total Liabilities for Regeneron Pharmaceuticals (REGN)
According to Regeneron Pharmaceuticals's latest reported financial statements, the company's latest reported total liabilities is $9.30B USD. Total liabilities sum everything the company owes at the end of each reporting period — accounts payable, accrued expenses, debt, lease obligations, and other claims — as filed on the balance sheet. Compare with total assets and net assets for solvency context.
Headline figure above is from the reporting period ending (reported ). Chart and table below cover the full reported history back to .
Currently viewingTotal LiabilitiesSwitch metric
Latest period
$9.30B
YoY change
+10.7%
5Y CAGR
+8.7%
Peak year (2025)
$9.30B
Latest annual
$9.30B
Total Liabilities history chart for Regeneron Pharmaceuticals (REGN) from 1990 to 2025
Total Liabilities history table for Regeneron Pharmaceuticals (REGN) from 1990 to 2025
| Fiscal year | Period ended | Reported | Total Liabilities | YoY |
|---|---|---|---|---|
| 2025 | $9.30B | +10.7% | ||
| 2024 | $8.41B | +18.3% | ||
| 2023 | $7.11B | +8.5% | ||
| 2022 | $6.55B | -1.7% | ||
| 2021 | $6.67B | +8.6% | ||
| 2020 | $6.14B | +65.2% | ||
| 2019 | $3.72B | +24.8% | ||
| 2018 | $2.98B | +13.6% | ||
| 2017 | $2.62B | +3.8% | ||
| 2016 | $2.52B | +29.2% | ||
| 2015 | $1.95B | +47.0% | ||
| 2014 | $1.33B | +33.1% | ||
| 2013 | $998.94M | +19.6% | ||
| 2012 | $835.11M | -0.3% | ||
| 2011 | $837.85M | +49.2% | ||
| 2010 | $561.62M | +63.1% | ||
| 2009 | $344.44M | +37.1% | ||
| 2008 | $251.19M | -47.2% | ||
| 2007 | $475.99M | +29.2% | ||
| 2006 | $368.47M | +19.1% | ||
| 2005 | $309.50M | +6.5% | ||
| 2004 | $290.56M | -15.0% | ||
| 2003 | $341.91M | +39.2% | ||
| 2002 | $245.59M | +7.2% | ||
| 2001 | $229.04M | +776.1% | ||
| 2000 | $26.14M | -4.9% | ||
| 1999 | $27.50M | +7.0% | ||
| 1998 | $25.70M | -12.9% | ||
| 1997 | $29.50M | -3.9% | ||
| 1996 | $30.70M | +18.5% | ||
| 1995 | $25.90M | -4.4% | ||
| 1994 | $27.10M | +41.1% | ||
| 1993 | $19.20M | +79.4% | ||
| 1992 | $10.70M | +37.2% | ||
| 1991 | $7.80M | -40.9% | ||
| 1990 | $13.20M | — |
Total Liabilities values are taken from Regeneron Pharmaceuticals's reported balance sheets (10-Q quarterly and 10-K annual filings with the U.S. Securities and Exchange Commission). Each row shows the period end date and the date the filing was reported; YoY compares each figure to the same period one year earlier. Amounts are in USD as filed.
Analysis
The 2025 reading of Regeneron Pharmaceuticals (REGN) total liabilities is $9.30B – grew 10.7% year-over-year.
Looking at the 2020–2025 (5 years) stretch, Regeneron Pharmaceuticals total liabilities compounded at +8.7% per year, with the latest reading among the more recent periods of the dataset.
Across the available history, total liabilities reached its high of $9.30B in 2025 and its low of $7.80M in 1991.
Among 8 Healthcare peers, Regeneron Pharmaceuticals (REGN) ranks 9th; the peer median for total liabilities is $101.80B.
Regeneron Pharmaceuticals Total Liabilities by Year
Regeneron Pharmaceuticals Total Liabilities 2025: $9.30B
Regeneron Pharmaceuticals total liabilities in 2025 was $9.30B, grew 10.7% from 2024. This figure represents the highest annual value in the available history.
Regeneron Pharmaceuticals Total Liabilities 2024: $8.41B
Regeneron Pharmaceuticals total liabilities in 2024 was $8.41B, grew 18.3% from 2023.
Regeneron Pharmaceuticals Total Liabilities 2023: $7.11B
Regeneron Pharmaceuticals total liabilities in 2023 was $7.11B, grew 8.5% from 2022.
Regeneron Pharmaceuticals Total Liabilities 2022: $6.55B
Regeneron Pharmaceuticals total liabilities in 2022 was $6.55B, edged down 1.7% below 2021.
Regeneron Pharmaceuticals Total Liabilities 2021: $6.67B
Regeneron Pharmaceuticals total liabilities in 2021 was $6.67B.
See more financial history for Regeneron Pharmaceuticals (REGN).
Sector peers — Total Liabilities
Companies in the same sector as Regeneron Pharmaceuticals, ranked by their latest total liabilities.
| Company | Total Liabilities | Sector |
|---|---|---|
| Novo Nordisk A/S (NVO) | $348.86B | Healthcare |
| UnitedHealth Group Incorporated (UNH) | $207.88B | Healthcare |
| AbbVie Inc. (ABBV) | $137.19B | Healthcare |
| Johnson & Johnson (JNJ) | $117.67B | Healthcare |
| Eli Lilly and Company (LLY) | $85.94B | Healthcare |
| Merck & Co., Inc. (MRK) | $84.20B | Healthcare |
| Amgen Inc. (AMGN) | $81.93B | Healthcare |
| AstraZeneca PLC (AZN) | $65.36B | Healthcare |
Frequently asked questions
What is Regeneron Pharmaceuticals's total liabilities?
- Latest reported total liabilities for Regeneron Pharmaceuticals (REGN) is $9.30B (period ending December 31, 2025).
How has Regeneron Pharmaceuticals total liabilities changed year-over-year?
- Regeneron Pharmaceuticals (REGN) total liabilities changed +10.7% year-over-year on the latest annual filing.
What is the long-term growth rate of Regeneron Pharmaceuticals total liabilities?
- Regeneron Pharmaceuticals (REGN) total liabilities compound annual growth rate is +8.7% over the most recent 5 years available.
When did Regeneron Pharmaceuticals total liabilities hit its highest annual value?
- Regeneron Pharmaceuticals total liabilities reached its highest annual value of $9.30B in 2025.
What was Regeneron Pharmaceuticals total liabilities in 2024?
- Regeneron Pharmaceuticals (REGN) total liabilities in 2024 was $8.41B.
What was Regeneron Pharmaceuticals total liabilities in 2025?
- Regeneron Pharmaceuticals (REGN) total liabilities in 2025 was $9.30B.
Metrics overview
Pick a metric for charts, filings, and peers — each row shows the latest TTM or annual value with year-over-year change.
Explore more
REGN Overview
Company profile, financial tools, and key metrics
REGN Revenue Counter
Earns $454.81 every second. See per minute, hour, and day.
REGN Earnings Counter
Earns $142.85 per second net profit. See per minute, hour, and day.
REGN Economic Scale
Exceeds Rwanda's GDP. Compare with world economies.
REGN What If Invested
What if you had invested $1,000? See historical returns from any date.
REGN How It Makes Money
Discover visual breakdown of $14.34B in revenue — where it comes from and where it goes.
REGN Stock Seasonality
Best and worst months to invest. Historical monthly returns heatmap.
REGN Price Target Scenarios
Model bear, base, and bull cases with EPS growth and exit P/E — pre-filled from analysts and history.
REGN Daily Price Character
Explosive · 47.1% historical win rate (green days). Streaks & record days.
REGN Buybacks
4.33% TTM buyback yield. Shareholder yield & SBC comparison.
REGN Dividend Profile
Yield: 0.52%. See full history.
REGN Dividend Calculator
How much dividend income would $1,000 have earned? Calculate from any date.
REGN Dividend Forecast
Project future income with DRIP, growth assumptions, and optional monthly contributions.